Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood diseases
Pharma
Sanofi sells rare disease med Enjaymo to Recordati for $825M
Recordati is paying $825 million upfront—plus $250 million in potential milestones—to pick up the global rights to Sanofi’s rare disease med Enjaymo.
Fraiser Kansteiner
Oct 4, 2024 10:11am
Pfizer pulls sickle cell disease drug Oxbryta from global markets
Sep 25, 2024 6:00pm
BioMarin downsizes gene therapy efforts to focus on 3 markets
Aug 6, 2024 10:34am
Agios charts broad path for oral thalassemia med after trial win
Jan 3, 2024 10:49am
Novartis shows strong Fabhalta results in another blood disorder
Dec 11, 2023 11:20am
Takeda keeps approval rolling with FDA nod for Adzynma
Nov 9, 2023 3:40pm
